RMD monthly performance report
Monthly RMD research: returns, drawdown, relative strength, seasonality, and key stats.
RMD monthly report
—
Key takeaways
- ResMed (RMD) closed August 2026 at $224.03, up 6.19% for the month and −21.39% over the trailing 12 months.
- Year-to-date, RMD is −6.99%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading −3.46% versus its 200-day moving average ($232.07), a cautious technical signal.
- Over the past three years, RMD has underperformed the S&P 500 by −47.30%, with a relative strength index reading of 70.3.
- Win rate over the trailing 39 months stands at 53.8% — 21 positive months versus 18 negative months.
ResMed ended August 2026 at $224.03, posting a monthly return of +6.19%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +3.14%.
The current quarter stands at +13.04% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −3.46% versus the 200-day moving average ($232.07).
Year-to-date, RMD is −6.99% against SPY +12.89%, a gap of −19.88%. The stock is currently −23.75% below its 52-week high, with maximum 3-year drawdown at −37.76%.
| Period | RMD | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.40% | −0.20% | +0.60% |
| 1 Week | +7.21% | +3.90% | +3.31% |
| 1 Month | +6.19% | +3.05% | +3.14% |
| 3 Months | +4.78% | +7.11% | −2.33% |
| 6 Months |